Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ARCA biopharma, Inc. ABIO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

ARCA biopharma, Inc. (ABIO) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

ABIO Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to ARCA biopharma, Inc. in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

CTMX
CTMX
CytomX Therapeutics, Inc.
$4.56
+0.44%
 FBRX
FBRX
Forte Biosciences, Inc.
$31.28
-3.52%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.64
-5.04%
 ADAG
ADAG
Adagene Inc.
$3.82
+0.26%
 ANTX
ANTX
AN2 Therapeutics, Inc.
$3.26
+9.40%
 AVTE
AVTE
Aerovate Therapeutics, Inc.
$2.68
+0.00%
 TIL
TIL
Instil Bio, Inc.
$8.89
+5.33%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message